Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mercredi, octobre 07
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
PDS Biotechnology Corp
PDSB
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$1.04
-0.16
-12.92%
Dern. MÀJ: Oct 7, 4:25 AM
$0.9803
-0.22
-18.31%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
PDS Biotechnology Financials
PDS Biotechnology (PDSB) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
PDS Biotechnology Q2 EPS $(0.18) Misses $(0.13) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.13) by 38.46 percent. This is a 14.29 percent increase over losses of $(0.21) per share
Benzinga Newsdesk
Earnings Scheduled For May 13, 2026
Benzinga Insights
PRO
PDS Biotechnology Q1 EPS $(0.13) Beats $(0.15) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 38.1 percent increase over losses of $(0.21) per share from
Benzinga Newsdesk
PRO
PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 33.33 percent increase over losses of $(0.21) per share from
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
PRO
PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M
Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and
Benzinga Newsdesk
